Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuronASX:IMC Debt-to-Equity is 0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, Immuron ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Immuron's Debt-to-Equity or its related term are showing as below:
ASX:IMC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.39
Current: 0.01
During the past 11 years, the highest Debt-to-Equity Ratio of Immuron was 0.39. The lowest was 0.00. And the median was 0.01.
ASX:IMC's Debt-to-Equity is ranked better than 99.9% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ASX:IMC: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Immuron Debt-to-Equity Related Terms
Immuron Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Immuron's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMC vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Immuron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Immuron's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Immuron's Debt-to-Equity too high?
Immuron's current Debt-to-Equity is 0.00. Based on the distribution chart, Immuron ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Immuron's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #1 out of 965 companies for Debt-to-Equity. This places Immuron in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (ASX:IMC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.04 — trading 81.3% below its estimated fair value. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 
